Effect of dapagliflozin on cardiac function and inflammatory factors in patients with heart failure with preserved ejection fraction and type 2 diabetes mellitus
10.3969/j.issn.1009-0754.2025.07.014
- VernacularTitle:达格列净对射血分数保留心力衰竭合并2型糖尿病患者心功能及炎症因子的影响
- Author:
Jing QIAO
1
;
Hui LI
;
Yun YANG
Author Information
1. 236600 安徽 阜阳,皖南医学院附属太和医院内分泌科
- Keywords:
Dapagliflozin;
Heart failure with preserved ejection fraction;
Type 2 diabetes mellitus;
Cardiac function
- From:
Journal of Navy Medicine
2025;46(7):716-720
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the potential effect of dapagliflozin on cardiac function and inflammatory factors in patients with heart failure with preserved ejection fraction(HFpEF)and type 2 diabetes mellitus(T2DM).Methods One hundred patients with heart failure and T2DM who were admitted to Taihe Hospital,Wannan Medical College from June 2021 to August 2023 were selected as research objects.According to the random number table,they were assigned to experimental group or control group(n=50).The control group received routine treatment,while the experimental group gave dapagliflozin apart from the routine treatment.The therapeutic effect,cardiac function,inflammatory factors,and adverse reactions were compared between the two groups.Results The experimental group had higher effective rate than the control group(96.00%vs 74.00%,P<0.05).After treatment,left ventricular ejection fraction(LVEF)increased in both groups,and LVEF in the experimental group was significantly higher than that in the control group(59.02%±4.72%vs 54.70%±4.10%,P<0.05).After treatment,left ventricular end-diastolic dimension(LVEDD),brain natriuretic peptide(BNP),interleukin 6(IL-6),procaicltonin(PCT),and C-reactive protein(CRP)were decreased in both groups,and these indexes in the experimental group was significantly lower than those in the control group([52.92±1.56]mm vs[55.70±2.19]mm,[200.63±75.73]ng/L vs[265.80±95.47]ng/L,[234.47±21.51]μg/L vs[307.51±27.81]μg/L,[6.23±2.51]μg/L vs[11.27±2.42]μg/L,[5.33±0.41]mg/L vs[6.82±0.73]mg/L,P<0.05).The incidence of adverse reactions in the experimental group was significantly lower than that in the control group(14.00%[7/50]vs 36.00%[18/50],P<0.05).Conclusion Dapagliflozin can improve cardiac function indexes and reduce inflammatory factor levels and adverse reactions in patients with HFpEF and T2DM.
